Literature DB >> 8516579

[Serum CA125 measurement is useful in 3 cases with pericardial effusion].

S Toshihiko1, U Megumi, H Takahiro, K Keizo, K Chikao, T Tsunenori, K Katsuya, F Hiroki, H Mitsuko.   

Abstract

Previously we reported that serum CA125 level is elevated in cases of pericardial effusion. We report three cases in which serum CA125 measurement is useful for assessing clinical status. In case 1, a 19-year-old came to our hospital for cardiac tamponade. Moderate degree of pericardial effusion and high CA125 level were observed. After the pericardectomy the serum CA125 level was normalized and pericardial effusion disappeared. Case 2, a 50-year-old man with mesothelioma and in whom serum CA125 level was elevated with pericardial effusion. After cardiac drainage his condition improved, with decreased CA125 level. However, later the CA125 level rose and recurrent localized pericardial effusion with worsening condition was observed. In case 3, in a 78-year-old woman with pericardial effusion no recurrence was observed after pericardial drainage. Her CA125 value was normal. These results indicated that measurement of CA125 value is a useful marker for assessing the clinical course of this disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8516579

Source DB:  PubMed          Journal:  Kokyu To Junkan        ISSN: 0452-3458


  2 in total

Review 1.  Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers.

Authors:  Michela Chianca; Giorgia Panichella; Iacopo Fabiani; Alberto Giannoni; Serena L'Abbate; Alberto Aimo; Annamaria Del Franco; Giuseppe Vergaro; Chrysanthos Grigoratos; Vincenzo Castiglione; Carlo Maria Cipolla; Antonella Fedele; Claudio Passino; Michele Emdin; Daniela Maria Cardinale
Journal:  Front Cardiovasc Med       Date:  2022-07-06

2.  Plasma carbohydrate antigen-125 for prediction of atrial fibrillation recurrence after radiofrequency catheter ablation.

Authors:  Qingya Wang; Chengjing Dang; Haoyu Liu; Jie Hui
Journal:  BMC Cardiovasc Disord       Date:  2021-08-19       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.